Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S. Hehlmann R, et al. J Clin Oncol. 2011 Apr 20;29(12):1634-42. doi: 10.1200/JCO.2010.32.0598. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422420 Clinical Trial.
[Drug therapy of chronic myeloid leukemia].
Hochhaus A, Berger U, Reiter A, Lahaye T, Kreil S, Hehlmann R. Hochhaus A, et al. Among authors: hehlmann r. Med Klin (Munich). 2002 Jan 15;97 Suppl 1:7-15. Med Klin (Munich). 2002. PMID: 11831070 German.
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Müller MC, Berg T, Gschaidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A. Burchert A, et al. Among authors: hehlmann r. Blood. 2003 Jan 1;101(1):259-64. doi: 10.1182/blood-2002-02-0659. Epub 2002 Jun 28. Blood. 2003. PMID: 12393722 Free article.
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Brümmendorf TH, Ersöz I, Hartmann U, Bartolovic K, Balabanov S, Wahl A, Paschka P, Kreil S, Lahaye T, Berger U, Gschaidmeier H, Bokemeyer C, Hehlmann R, Dietz K, Lansdorp PM, Kanz L, Hochhaus A. Brümmendorf TH, et al. Among authors: hehlmann r. Blood. 2003 Jan 1;101(1):375-6. doi: 10.1182/blood-2002-08-2557. Blood. 2003. PMID: 12485943 Free article. No abstract available.
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Brummendorf TH, Ersoz I, Hartmann U, Balabanov S, Wolke H, Paschka P, Lahaye T, Berner B, Bartolovic K, Kreil S, Berger U, Gschaidmeier H, Bokemeyer C, Hehlmann R, Dietz K, Lansdorp PM, Kanz L, Hochhaus A. Brummendorf TH, et al. Among authors: hehlmann r. Ann N Y Acad Sci. 2003 May;996:26-38. doi: 10.1111/j.1749-6632.2003.tb03229.x. Ann N Y Acad Sci. 2003. PMID: 12799279 Clinical Trial.
468 results